Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment

Dong I.I. Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasuo Suzuki, Kentaro Sugano, Mamoru WatanabeToshifumi Hibi, Amarender S. Puri, Suk Kyun Yang

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asian Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection, and prevention of latent TB infection and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment. Twenty-three consensus statements were initially drafted and then discussed by the committee members. The quality of evidence and the strength of recommendations were assessed by using the Grading of Recommendations Assessment, Development, and Evaluation methodology. Web-based consensus voting was performed by 211 IBD specialists from nine Asian countries concerning each statement. A consensus statement was accepted if at least 75% of the participants agreed. Part 1 of the statements comprised two parts: (i) risk of TB infection during anti-TNF therapy and (ii) screening for TB infection prior to commencing anti-TNF therapy. These consensus statements will help clinicians optimize patient outcomes by reducing the morbidity and mortality related to TB infections in patients with IBD receiving anti-TNF treatment.

Original languageEnglish
Pages (from-to)20-29
Number of pages10
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume33
Issue number1
DOIs
StatePublished - 2018 Jan 1

Fingerprint

Gastroenterology
Colitis
Inflammatory Bowel Diseases
Tuberculosis
Tumor Necrosis Factor-alpha
Organizations
Infection
Therapeutics
Committee Membership
Latent Tuberculosis
Politics
Developing Countries
Morbidity
Mortality
Health

Keywords

  • anti-TNF
  • consensus statement
  • inflammatory bowel disease
  • tuberculosis

Cite this

Park, Dong I.I. ; Hisamatsu, Tadakazu ; Chen, Minhu ; Ng, Siew Chien ; Ooi, Choon Jin ; Wei, Shu Chen ; Banerjee, Rupa ; Hilmi, Ida Normiha ; Jeen, Yoon Tae ; Han, Dong Soo ; Kim, Hyo Jong ; Ran, Zhihua ; Wu, Kaichun ; Qian, Jiaming ; Hu, Pin Jin ; Matsuoka, Katsuyoshi ; Andoh, Akira ; Suzuki, Yasuo ; Sugano, Kentaro ; Watanabe, Mamoru ; Hibi, Toshifumi ; Puri, Amarender S. ; Yang, Suk Kyun. / Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1 : Risk assessment. In: Journal of Gastroenterology and Hepatology (Australia). 2018 ; Vol. 33, No. 1. pp. 20-29.
@article{fca07a4723af4fd7b150d525f5ad3b2d,
title = "Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment",
abstract = "Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asian Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection, and prevention of latent TB infection and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment. Twenty-three consensus statements were initially drafted and then discussed by the committee members. The quality of evidence and the strength of recommendations were assessed by using the Grading of Recommendations Assessment, Development, and Evaluation methodology. Web-based consensus voting was performed by 211 IBD specialists from nine Asian countries concerning each statement. A consensus statement was accepted if at least 75{\%} of the participants agreed. Part 1 of the statements comprised two parts: (i) risk of TB infection during anti-TNF therapy and (ii) screening for TB infection prior to commencing anti-TNF therapy. These consensus statements will help clinicians optimize patient outcomes by reducing the morbidity and mortality related to TB infections in patients with IBD receiving anti-TNF treatment.",
keywords = "anti-TNF, consensus statement, inflammatory bowel disease, tuberculosis",
author = "Park, {Dong I.I.} and Tadakazu Hisamatsu and Minhu Chen and Ng, {Siew Chien} and Ooi, {Choon Jin} and Wei, {Shu Chen} and Rupa Banerjee and Hilmi, {Ida Normiha} and Jeen, {Yoon Tae} and Han, {Dong Soo} and Kim, {Hyo Jong} and Zhihua Ran and Kaichun Wu and Jiaming Qian and Hu, {Pin Jin} and Katsuyoshi Matsuoka and Akira Andoh and Yasuo Suzuki and Kentaro Sugano and Mamoru Watanabe and Toshifumi Hibi and Puri, {Amarender S.} and Yang, {Suk Kyun}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/jgh.14019",
language = "English",
volume = "33",
pages = "20--29",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
number = "1",

}

Park, DII, Hisamatsu, T, Chen, M, Ng, SC, Ooi, CJ, Wei, SC, Banerjee, R, Hilmi, IN, Jeen, YT, Han, DS, Kim, HJ, Ran, Z, Wu, K, Qian, J, Hu, PJ, Matsuoka, K, Andoh, A, Suzuki, Y, Sugano, K, Watanabe, M, Hibi, T, Puri, AS & Yang, SK 2018, 'Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment', Journal of Gastroenterology and Hepatology (Australia), vol. 33, no. 1, pp. 20-29. https://doi.org/10.1111/jgh.14019

Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1 : Risk assessment. / Park, Dong I.I.; Hisamatsu, Tadakazu; Chen, Minhu; Ng, Siew Chien; Ooi, Choon Jin; Wei, Shu Chen; Banerjee, Rupa; Hilmi, Ida Normiha; Jeen, Yoon Tae; Han, Dong Soo; Kim, Hyo Jong; Ran, Zhihua; Wu, Kaichun; Qian, Jiaming; Hu, Pin Jin; Matsuoka, Katsuyoshi; Andoh, Akira; Suzuki, Yasuo; Sugano, Kentaro; Watanabe, Mamoru; Hibi, Toshifumi; Puri, Amarender S.; Yang, Suk Kyun.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 33, No. 1, 01.01.2018, p. 20-29.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1

T2 - Risk assessment

AU - Park, Dong I.I.

AU - Hisamatsu, Tadakazu

AU - Chen, Minhu

AU - Ng, Siew Chien

AU - Ooi, Choon Jin

AU - Wei, Shu Chen

AU - Banerjee, Rupa

AU - Hilmi, Ida Normiha

AU - Jeen, Yoon Tae

AU - Han, Dong Soo

AU - Kim, Hyo Jong

AU - Ran, Zhihua

AU - Wu, Kaichun

AU - Qian, Jiaming

AU - Hu, Pin Jin

AU - Matsuoka, Katsuyoshi

AU - Andoh, Akira

AU - Suzuki, Yasuo

AU - Sugano, Kentaro

AU - Watanabe, Mamoru

AU - Hibi, Toshifumi

AU - Puri, Amarender S.

AU - Yang, Suk Kyun

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asian Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection, and prevention of latent TB infection and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment. Twenty-three consensus statements were initially drafted and then discussed by the committee members. The quality of evidence and the strength of recommendations were assessed by using the Grading of Recommendations Assessment, Development, and Evaluation methodology. Web-based consensus voting was performed by 211 IBD specialists from nine Asian countries concerning each statement. A consensus statement was accepted if at least 75% of the participants agreed. Part 1 of the statements comprised two parts: (i) risk of TB infection during anti-TNF therapy and (ii) screening for TB infection prior to commencing anti-TNF therapy. These consensus statements will help clinicians optimize patient outcomes by reducing the morbidity and mortality related to TB infections in patients with IBD receiving anti-TNF treatment.

AB - Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asian Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection, and prevention of latent TB infection and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment. Twenty-three consensus statements were initially drafted and then discussed by the committee members. The quality of evidence and the strength of recommendations were assessed by using the Grading of Recommendations Assessment, Development, and Evaluation methodology. Web-based consensus voting was performed by 211 IBD specialists from nine Asian countries concerning each statement. A consensus statement was accepted if at least 75% of the participants agreed. Part 1 of the statements comprised two parts: (i) risk of TB infection during anti-TNF therapy and (ii) screening for TB infection prior to commencing anti-TNF therapy. These consensus statements will help clinicians optimize patient outcomes by reducing the morbidity and mortality related to TB infections in patients with IBD receiving anti-TNF treatment.

KW - anti-TNF

KW - consensus statement

KW - inflammatory bowel disease

KW - tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=85039418895&partnerID=8YFLogxK

U2 - 10.1111/jgh.14019

DO - 10.1111/jgh.14019

M3 - Review article

C2 - 29023903

AN - SCOPUS:85039418895

VL - 33

SP - 20

EP - 29

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 1

ER -